NDAINHALATIONSOLUTION
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
5/8 — Partial
LONHALA MAGNAIR KIT (glycopyrrolate) by Sumitomo Dainippon Pharma is tissues, including salivary glands. Approved for chronic obstructive pulmonary disease, neuromuscular blockade reversal. First approved in 2017.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LONHALA MAGNAIR KIT is an inhaled solution of glycopyrrolate, a long-acting anticholinergic (muscarinic antagonist) approved for chronic obstructive pulmonary disease (COPD). It works by blocking muscarinic receptors on airway smooth muscle and reducing acetylcholine-mediated bronchoconstriction, delivered via the proprietary MAGNAIR nebulizer system. The product targets patients requiring maintenance bronchodilation therapy for COPD symptom management.
Peak10.6 years to LOE
Product is in peak revenue phase with extended patent protection through 2036; brand teams are likely focused on market maintenance and differentiation against strong competitive entrants rather than growth.
Mechanism of Action
tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors.
Worked on LONHALA MAGNAIR KIT at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.